Acquisition Synergy Forma Therapeutics is now Novo Nordisk, presenting a direct cross-sell opportunity for Novo Nordisk capabilities, expanded global reach, and integration of Forma's biotech expertise into Novo Nordisk's existing portfolio.

North American Footprint Headquartered in Watertown, MA with 51-200 employees, there is potential to target Novo Nordisk’s regional teams and leverage local relationships to introduce Novo Nordisk capabilities in biotech research services, collaboration opportunities, and equipment sourcing.

Digital & Data Upsell The tech stack includes Optimizely, Experian, Tellius, MLflow, Linux, and data-centric tools, signaling readiness for advanced analytics, experimentation, and cloud-based R&D optimization services that can be offered to streamline Novo Nordisk’s research pipelines.

Global Expansion & Manufacturing Recent news highlights new or expanded facilities in the Czech Republic and China, indicating ongoing capacity growth and the need for validated biotechnology manufacturing, supply chain robustness, and regional compliance consulting services.

Cybersecurity & Risk Multiple security incidents and data breach claims point to a priority area for risk assessment, secure IT modernization, and governance solutions to protect R&D data, clinical information, and manufacturing IP.